Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
Kymera Therapeutics will report Phase 1 healthy volunteer trial results for KT-579, its first-in-class oral IRF5 degrader, on October 29, 2026, alongside previously scheduled Q3 2026 financial results. The company will host a video conference call and webcast at 8:30 a.m. ET that day.
Key figures
- Drug Name
- KT-579
- Phase Of Trial
- Phase 1
- Webcast time
- 8:30 a.m. ET October 29, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.